Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 611

recruiting
3 972
countries
28
conditions
2 104

10 284 trials match your criteria

Study on the Safety and Imaging of Risankizumab-800CW for Patients with Inflammatory Bowel Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab

Marginal zone lymphoma+3

Not recruiting

Study of Obinutuzumab as First-Line Treatment for Adult Patients with Marginal Zone Lymphoma Who Are Not Eligible for Local Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab

Endometrial cancer+1

Not recruiting

Study of NP137 with carboplatin, paclitaxel and pembrolizumab combination therapy for patients with advanced endometrial or cervical cancer who had prior chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Gastric cancer

Not recruiting

Study of spartalizumab combined with FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, docetaxel) for patients with resectable gastric cancer before and after surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel

Obesity

Not recruiting

Study of Tirzepatide for Reducing Obesity and Related Health Issues in Adolescents

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Tirzepatide

Multiple sclerosis

Not recruiting

Study on the Effectiveness of Tamsulosin for Treating Urinary Symptoms in Women with Multiple Sclerosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tamsulosin Hydrochloride

Study Comparing Toripalimab and Lenvatinib with Placebo and Lenvatinib for First-Line Treatment in Patients with Advanced Liver Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib

Study on Basimglurant for Children, Adolescents, and Young Adults with Tuberous Sclerosis Complex-Related Seizures

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Basimglurant

Psoriasis

Not recruiting

Study of deucravacitinib in adults with plaque psoriasis: Effects on immune system cells

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib

Uveal melanoma

Not recruiting

Study of AloCelyvir for Patients with Metastatic Uveal Melanoma

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Allogenic Bone Marrow-Derived Mesenchymal Stem Cells Transduced With Icovir-5, Ex Vivo Expanded

Study on the Effectiveness of OPT-302 and Ranibizumab for Patients with Wet Age-related Macular Degeneration

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab

Gastric cancer

Not recruiting

Study of Preoperative FLOT4 and Intraperitoneal Chemotherapy with Hyperthermia (HIPEC) for Advanced Gastric Cancer Patients at High Risk of Peritoneal Metastases

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.